PHRX.CN Pharmadrug CNQ down 33.33% to C$0.01 on 17 Feb 2026: liquidity risks

PHRX.CN stock plunged -33.33% to C$0.01 on 17 Feb 2026 during market hours on the CNQ in Canada. The drop follows a one-day move from an open of C$0.02 to a low of C$0.01, with 28,921.00 shares traded. Intraday volume remained below the 50-day average, flagging limited liquidity and higher volatility. Investors should watch cash runway, research partnerships and short-term catalysts before considering positions in Pharmadrug Inc.

PHRX.CN stock: intraday price action and volume

Pharmadrug Inc. (PHRX.CN) moved from an open of C$0.02 to a close at C$0.01 today, a -33.33% one-day change. Volume finished at 28,921.00, below the average volume of 37,944.00, which indicates thinner trading and larger price swings on small orders.

Volume, liquidity and shares outstanding

Low liquidity is the main immediate concern for PHRX.CN stock holders because the company has 108,234,380.00 shares outstanding and a market cap of C$1,082,344.00. The relative volume of 0.76 shows trading interest is muted, raising execution risk for larger orders.

Financials, ratios and valuation for PHRX.CN stock

Pharmadrug shows weak operating metrics with EPS of -0.01 and a trailing PE of -1.00, reflecting losses. Key ratios highlight stress: current ratio 0.01 and book value per share -0.01, signalling thin cash buffers and negative equity per share. Enterprise value at C$2,566,315.00 outpaces market cap, reflecting debt and obligations.

Catalysts, risks and healthcare sector context

Pharmadrug operates in Healthcare, a sector with YTD weakness of -4.11%, which adds headwinds for small-cap drug makers. The company lists research agreements with Johns Hopkins and University of Michigan, offering long-term upside. One immediate risk is cash runway and regulatory hurdles for psychedelics and controlled-substance projects.

Technical snapshot and trading signals for PHRX.CN stock

Technical indicators show momentum weakening: RSI 33.39 and ADX 51.66, which signals a strong trend to the downside. Bollinger Bands sit at upper 0.02 and lower 0.01, implying tight price range. Short-term support sits at the year low C$0.01, with resistance near the 50-day average C$0.02.

Meyka AI grade and model forecast for PHRX.CN

Meyka AI rates PHRX.CN with a score out of 100: 67.87 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly price of C$0.01, roughly in line with the current price, and flags limited upside in the near term. Forecasts are model-based projections and not guarantees.

Final Thoughts

PHRX.CN stock traded lower by -33.33% to C$0.01 on 17 Feb 2026, driven by thin volume and weak fundamentals. Short-term technicals and liquidity create trading risk for larger positions, while sector headwinds in Healthcare add pressure. For investors, we set a conservative near-term price target range: C$0.005 (bear), C$0.01 (base), C$0.02 (bull). Meyka AI’s forecast model projects a monthly price of C$0.01, implying 0.00% near-term change versus the current price. These targets reflect high execution risk, negative EPS of -0.01, and a market cap of C$1,082,344.00. Forecasts are model-based projections and not guarantees. Use small position sizing, confirm cash runway updates, and watch upcoming catalysts such as the May earnings announcement and clinical progress before adjusting exposure. For a quick company profile, see Pharmadrug’s site and our internal page at PHRX.CN on Meyka. source source Meyka AI provides this as an AI-powered market analysis platform and not financial advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.